Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis

13 Oct 2021

Abstract excerpt

BACKGROUND: There is an increasing number of papers reporting the real world use of Nusinersen in different cohorts of SMA patients. MAIN BODY: The aim of this paper was to critically review the literature reporting real world data on motor function in type 2 and 3 patients treated with Nusinersen, subdividing the results according to SMA type, age and type of assessment and performing a meta-analysis of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Hereditary Neurological Disorders
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34645478
DOI: 10.1186/s13023-021-02065-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysisPMID 34645478Read ↗

Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in western ChinaSemantic proximity Read ↗

Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type.Semantic proximity Read ↗

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity Read ↗

Effect of nusinersen after three years of treatment in 61 young children with SMA type 1 or 2: a French real-life observational studySemantic proximity Read ↗

Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3Semantic proximity Read ↗

New treatments in spinal muscular atrophy.Semantic proximity Read ↗

The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular AtrophySemantic proximity Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

New Directions for SMA TherapySemantic proximity Read ↗

Deficiencies in the medical care of SMA: evidence from a nationwide patient registry in GermanySemantic proximity Read ↗

New Treatments in Spinal Muscular Atrophy: Positive Results and New ChallengesSemantic proximity Read ↗

The respiratory impact of novel therapies for spinal muscular atrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.